Medications Modulating the Acid Sphingomyelinase/Ceramide System and 28-Day Mortality among Patients with SARS-CoV-2: An Observational Study.

Hoertel N, Rezaei K, Sánchez-Rico M, Delgado-Álvarez A, Kornhuber J, Gulbins E, Olfson M, Ouazana-Vedrines C, Carpinteiro A, Cougoule C, Becker KA, Alvarado JM, Limosin F (2023)

Publication Language: English

Publication Type: Journal article

Publication year: 2023

Journal

Pharmaceuticals MDPI

Book Volume: 16

Article Number: 1107

Journal Issue: 8

DOI: 10.3390/ph16081107

Abstract

Prior evidence indicates the potential central role of the acid sphingomyelinase (ASM)/ceramide system in the infection of cells with SARS-CoV-2. We conducted a multicenter retrospective observational study including 72,105 adult patients with laboratory-confirmed SARS-CoV-2 infection who were admitted to 36 AP-HP (Assistance Publique-Hôpitaux de Paris) hospitals from 2 May 2020 to 31 August 2022. We examined the association between the ongoing use of medications functionally inhibiting acid sphingomyelinase (FIASMA), which reduces the infection of cells with SARS-CoV-2 in vitro, upon hospital admission with 28-day all-cause mortality in a 1:1 ratio matched analytic sample based on clinical characteristics, disease severity and other medications (N = 9714). The univariate Cox regression model of the matched analytic sample showed that FIASMA medication use at admission was associated with significantly lower risks of 28-day mortality (HR = 0.80; 95% CI = 0.72-0.88; p < 0.001). In this multicenter observational study, the use of FIASMA medications was significantly and substantially associated with reduced 28-day mortality among adult patients hospitalized with COVID-19. These findings support the continuation of these medications during the treatment of SARS-CoV-2 infections. Randomized clinical trials (RCTs) are needed to confirm these results, starting with the molecules with the greatest effect size in the study, e.g., fluoxetine, escitalopram, and amlodipine.

Authors with CRIS profile

Johannes Kornhuber Lehrstuhl für Psychiatrie und Psychotherapie

Involved external institutions

Hôpital Hôtel-Dieu, APHP FR France (FR) Université Paris Cité FR France (FR) Hôpital Corentin-Celton, Hospital Corentin-Celton, APHP FR France (FR) Universitätsklinikum Essen DE Germany (DE) Université Fédérale de Toulouse Midi-Pyrénées FR France (FR) New York State Psychiatric Institute (NYSPI) US United States (USA) (US) Universidad Complutense de Madrid (UCM) ES Spain (ES)

How to cite

APA:

Hoertel, N., Rezaei, K., Sánchez-Rico, M., Delgado-Álvarez, A., Kornhuber, J., Gulbins, E.,... Limosin, F. (2023). Medications Modulating the Acid Sphingomyelinase/Ceramide System and 28-Day Mortality among Patients with SARS-CoV-2: An Observational Study. Pharmaceuticals, 16(8). https://doi.org/10.3390/ph16081107

MLA:

Hoertel, Nicolas, et al. "Medications Modulating the Acid Sphingomyelinase/Ceramide System and 28-Day Mortality among Patients with SARS-CoV-2: An Observational Study." Pharmaceuticals 16.8 (2023).

BibTeX: Download